Evidence map›Paper›PMID 40214308›Full record

ArticleAdvanced materials (Deerfield Beach, Fla.)2025

Combination Treatment of Rituximab and Therapeutic Vaccines Affords Superior Tumor Suppression and Relapse Prevention for Non-Hodgkin Lymphoma.

Tong Qi, Jimin Guo, Zheng Cao, Shilin Chen, Eugene Kimura, Xiyao Li, Emiko Kranz, Xinheng Guo, Wenting Chen, Zi Wang and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced materials (Deerfield Beach, Fla.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Tong QiDepartment of Chemical and Biomolecular Engineering, University of California Los Angeles, Los Angeles, CA, 90095, USA.ORCID https://orcid.org/0009-0005-2198-5157
Jimin GuoUCLA AIDS Institute, University of California Los Angeles, Los Angeles, CA, 90095, USA.
Zheng CaoDepartment of Chemical and Biomolecular Engineering, University of California Los Angeles, Los Angeles, CA, 90095, USA.
Shilin ChenDepartment of Chemical and Biomolecular Engineering, University of California Los Angeles, Los Angeles, CA, 90095, USA.
Eugene KimuraUCLA AIDS Institute, University of California Los Angeles, Los Angeles, CA, 90095, USA.
Xiyao LiDepartment of Bioengineering, University of California Los Angeles, Los Angeles, CA, 90095, USA.
Emiko KranzUCLA AIDS Institute, University of California Los Angeles, Los Angeles, CA, 90095, USA.
Xinheng GuoDepartment of Chemical and Biomolecular Engineering, University of California Los Angeles, Los Angeles, CA, 90095, USA.
Wenting ChenDepartment of Chemical and Biomolecular Engineering, University of California Los Angeles, Los Angeles, CA, 90095, USA.
Zi WangDepartment of Chemical and Biomolecular Engineering, University of California Los Angeles, Los Angeles, CA, 90095, USA.
Cun-Yu WangDepartment of Bioengineering, University of California Los Angeles, Los Angeles, CA, 90095, USA.
Yunfeng LuDepartment of Chemical and Biomolecular Engineering, University of California Los Angeles, Los Angeles, CA, 90095, USA.
Jing WenUCLA AIDS Institute, University of California Los Angeles, Los Angeles, CA, 90095, USA.ORCID https://orcid.org/0000-0002-6127-6276

Funding

UCLA Clinical Translational Science InstituteUL1TR001881 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARLEEN F. BROWN, ARASH NAEIM · 2016 to 2026
$118.1M
Virology CoreP30AI028697 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ZACK, JEROME A. · 1991 to 2018
$39.9M
Targeting delivery of mAbs to CNS metastasesR01CA253215 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WEN, JING · 2020 to 2024
$1.7M
NCATS NIH HHS UL1 TR001881NCI NIH HHS R01 CA253215NIAID NIH HHS P30 AI028697
6 · The paper itself

Abstract

Lymphoma, a common malignancy of the lymphatic system, presents considerable health challenges and imposes a significant economic burden. Despite advancements in chemotherapy and immunotherapy that have improved survival rates, issues such as high relapse rates and treatment resistance remain pressing concerns. This study presents a novel therapeutic strategy that combines rituximab with a therapeutic vaccine for human B-cell non-Hodgkin lymphoma, evaluated in a humanized mouse model. This combination therapy synergistically achieves superior tumor suppression and relapse prevention. By harnessing the tumor-killing efficacy of monoclonal antibodies and the T cell-mediated immunity elicited by vaccines, this approach represents a promising advancement in achieving significantly improved cancer treatment outcomes.

Indexed as

Cancer VaccinesLymphoma, Non-HodgkinRituximabAnimalsCell Line, TumorHumansMiceNeoplasm Recurrence, LocalCancer VaccinesRituximabBLT humanized mouse modelimmunotherapynon‐Hodgkin lymphomasynergy therapytherapeutic cancer vaccines

Identifiers

PMID40214308
PMCPMC12227277

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.